In addition, pharmaceutical inhibition of the NFκB pathway by targeted drugs in relapsed primary MM samples ex vivo could be used to assess potential changes in BCL2A1/BFL-1, BCL2L1/BCL-XL, and BCL2/BCL-2 mRNA and protein expression. Here, NFKB1 is linked to Miyoshi myopathy.